Academic Journals Database
Disseminating quality controlled scientific knowledge

CD26: A prognostic marker of other systemic malignancies besides colo-rectal carcinomas

Author(s): Shailendra Kapoor

Journal: World Journal of Clinical Oncology
ISSN 2218-4333

Volume: 3;
Issue: 8;
Start page: 126;
Date: 2012;
Original page

Keywords: CD26 | Cancer | Carcinogenesis | Colon cancer | Marker

I read with great interest the recent article by Cordero et al in a recent issue of your esteemed journal. Interestingly, the past few years have seen the emergence of CD26 as an important diagnostic and prognostic marker for a number of systemic malignancies besides colo-rectal carcinomas. For instance, serum CD26 levels are an important emerging marker of B-cell chronic lymphocytic leukemia (B-CLL). In fact, Molica et al have recently reported shorter time to first treatment in B-CLL which exhibit higher serum CD26 levels and simultaneously demonstrate absence of mutation in IgV (H). Similarly, CD26 serves as a marker of poor prognosis in T cell lymphomas. Simultaneously, a poor response to 2’-deoxycoformycin is seen T cell lymphomas expressing CD26. Similarly, breast carcinomas exhibit decreased CD26 mean fluorescence intensity and a decreased percentage of CD26 positive lymphocytes in comparison to benign breast tumors and healthy individuals.

Tango Jona
Tangokurs Rapperswil-Jona

RPA Switzerland

RPA Switzerland

Robotic process automation